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INTRODUCTION
Repair of articular cartilage injuries remains a challenge, despite the development of surgical treatments such as microfracture, abrasion arthroplasty, and spongialization, which are used with the goal of recruiting marrow-derived cells by penetration of the subchondral bone. While these techniques promote increased short-term healing, long-term repair still consists of mechanically-inferior fibrocartilage 1 . Recent research has focused on tissue engineering strategies using scaffolds to improve cartilage repair and regeneration. In particular, hydrogels made from materials such as chitosan-glycerol phosphate 2 , polyethyleneglycol (PEG) 3 , fibrin 4 , polyglycolic-co-lactic acid (PLGA) 5 , and collagen 6 have been explored with the goal of improving the accumulation of extracellular matrix produced by cells (e.g., bone marrow stromal cells (BMSCs)) migrating into the scaffold from marrow.
Stimulation of BMSC chondrogenesis in vitro and in vivo has received much attention. In vitro studies have shown that transforming growth factor-β1 (TGF-β1), dexamethasone, and insulin-like growth factor-1 (IGF-1) promote chondrogenesis of BMSCs [7] [8] [9] [10] [11] , and methods for delivering these chondrogenic factors have been developed, often in conjunction with scaffolds [12] [13] [14] [15] . There have been a number of in vivo studies performed delivering IGF-1 4, 16 , TGF-β1 1, 17, 18 , or the combination of IGF-1 and TGF-β1 13, 16, 19 to cartilage defects in order to stimulate chondrogenesis of endogenous BMSCs, but to our knowledge, no in vivo studies have incorporated dexamethasone.
The hypothesis that delivery of exogenous BMSCs to the joint can enhance cartilage regeneration has prompted the exploration of a wide variety of growth factor and scaffold combinations to stimulate BMSC chondrogenesis 1, 20, 21 . In vivo studies have attempted to deliver BMSCs alone 22, 23 , BMSCs encapsulated in scaffolds [24] [25] [26] , and BMSCs encapsulated in scaffolds with the inclusion of TGF-β1 [27] [28] [29] [30] . Despite the in vitro promise shown by 3D-cultured BMSCs, most long-term in vivo treatments with BMSCs have resulted in sub-optimal cartilage repair tissue 20, 22, 24, 26 . Improving BMSC chondrogenesis in vivo is likely dependent on several factors that are not well understood, including cell delivery, microenvironment, and a combination of pro-chondrogenic longitudinal signaling. In addition, an ideal clinical approach would minimize or obviate the in vitro culture duration and be performed with a single arthroscopic procedure.
Recent studies have shown that hydrogels made from the self-assembling peptide sequences (RADA) 4 and (KLDL) 3 (hereafter referred to as KLD) can maintain the chondrocyte phenotype 31 and stimulate chondrogenesis of BMSCs in vitro [32] [33] [34] . These hydrogels have the ability to rapidly assemble when exposed to physiological pH and ionic strength 35 and have pore sizes in the range of 100-500 nm 36 . These synthetic peptides have been used in vivo without immunogenic reaction 37 . Furthermore, TGF-β1 has been shown to adsorb to KLD when pre-mixed with the peptide solution prior to assembly, resulting in extended delivery of TGF-β1 to BMSCs and stimulating chondrogenesis in vitro, promoting sGAG production and accumulation comparable to continuous medium supplementation of TGF-β1 over 21 days 38 . In addition, including dexamethasone with TGF-β1 in medium supplementation during the in vitro culture of BMSCs in RADA results in less catabolic cleavage of aggrecan compared to culture with TGF-β1 alone 39 . Finally, IGF-1 can be tethered to peptide scaffolds via biotin-streptavidin bonds; this tethered IGF-1 has been shown to remain biologically active and to promote cell survival in rat cardiomyocytes over 28 days 37 .
The goal of this study was to test the ability of an injectable KLD hydrogel with or without BMSCs and chondrogenic factors (CF) to stimulate cartilage regeneration in vivo in a critically-sized rabbit full-thickness cartilage defect model. This model provides access to the marrow, analogous to abrasion arthroplasty or spongialization in large animal models. We used CF treatments (IGF-1, TGF-β1, and dexamethasone) to test the hypotheses that CF would stimulate chondrogenesis and matrix production (1) by cells migrating into acellular KLD and (2) by P2 passaged allogeneic BMSCs delivered in KLD. IGF-1 was tethered to the peptide with a biotin-streptavidin bond 37 to stimulate long-term production of cartilage ECM, while TGF-β1 and dexamethasone were pre-mixed with KLD prior to BMSC encapsulation to stimulate chondrogenesis and initial matrix production. A 12-week timepoint enabled evaluation of mid-term benefits of the treatment compared to contralateral untreated defects.
METHODS

Materials
KLD peptide with the sequence AcN-(KLDL) 3 -CNH 2 was synthesized by the MIT Biopolymers Laboratory (Cambridge, MA) using an ABI Model 433A peptide synthesizer with FMOC protection. Human recombinant TGF-β1 (R&D Systems, Inc., Minneapolis, MN), dexamethasone (Sigma-Aldrich, St. Louis, MO), sucrose (Sigma-Aldrich), biotinylated-IGF-1 (bIGF-1) (immunological and biochemical testsystems GmbH, Reutlingen Germany), streptavidin (Pierce Biotechnology, Inc, Rockford, IL), biotinylated-KLD (biotin-(aminocaproic acid) 3 -(KLDL) 3 or b-KLD) (MIT Biopolymers Laboratory), FBS (Invitrogen, Carlsbad, CA), and FGF-2 (R&D Systems, Inc.) were purchased and used as described.
Cell Isolation
Bone marrow was harvested and pooled from four rabbits used for an initial pilot study, and BMSCs were isolated as previously described 34 . BMSCs were selected via differential adhesion to plastic and expanded two passages in alphaMEM with 10% FBS and 2 ng/mL FGF-2, 10 mM HEPES, and PSA (100 U/mL penicillin, 100 μg/mL streptomycin, and 250 ng/mL amphotericin), resulting in a total of approximately four population doublings. Each passage was conducted by seeding at a concentration of 12×10 3 BMSCs/cm 2 and incubating for two days to allow BMSCs to grow to ~75% confluence.
In Vivo Study Design
All procedures were approved by the Animal Care and Use Committees at Colorado State University and Massachusetts Institute of Technology. Twenty skeletally mature, retired, female breeder New Zealand White rabbits (average age 11 months and body weight 4.7 kg) were used for this study (Myrtle's Rabbitry, Thompson Station, TN). One rabbit died during the study due to neurologic problems post-surgery and was not included in the analysis. The n values shown in Table 1 do not reflect this animal. Three different groups were tested against contralateral, untreated, empty controls: (1) KLD, (2) KLD+chondrogenic factors (CF), and (3) KLD+CF+BMSCs (Table 1) . For all groups, KLD was resuspended in 10% sterile sucrose, and the final KLD concentration was kept constant at 3.2 mg/mL. For groups 2 and 3, KLD peptide (48 μg) was pre-mixed with a CF mixture consisting of 1.4 ng TGF-β1, 0.6 ng dexamethasone, 4.1 ng biotinylated-IGF-1 (bIGF-1), 30.7 ng streptavidin, and 0.48 μg b-KLD. For group 3, 150×10 3 BMSCs were encapsulated in the KLD/CF mixture 34 . Encapsulation of BMSCs in vitro in this manner resulted in 80-90% viability. In vitro studies indicated that this amount of TGF-β1 would result in a concentration of TGF-β1 inside the scaffold sufficient to stimulate chondrogenesis 38 . At the same time, if all of the TGF-β1 were to be released from the scaffold at once into the joint space in vivo, it would amount to approximately 1 ng/mL concentration in the joint space (1.4 ng/1.4 mL joint space volume 40 ), compared to the native concentration of 52.3 pg/mL found in adult rabbits 40 . Streptavidin and bIGF-1 were mixed at a 1:1 molar ratio in order to achieve, on average, binding of one bIGF-1 to each streptavidin allowing streptavidin to still bind b-KLD (in 100x molar excess of streptavidin and bIGF-1 to ensure homogeneous distribution of IGF-1 throughout the gel). The ability of this tethering to occur using these molar ratios has been shown in vitro and in vivo 37 . The amount of bIGF-1 tethered was chosen to provide a local concentration of 300 ng/mL inside the scaffold, which is above the threshold shown to be sufficient for chondrocyte stimulation of proteoglycan synthesis in vivo 41 .
Defect Creation and Gel Injection
All surgical procedures were performed under inhalation general anesthesia. A medialparapatellar arthrotomy approach to the femoropatellar joint was performed, and the patella was luxated laterally. A 3mm-diam × 2mm-deep full-thickness, critically-sized defect was created in the central region of the femoral trochlear groove (Fig 1) . Direct pressure was applied with a surgical sponge to ensure all bleeding was stopped prior to application of the peptide, which was delivered as a liquid. Defects were filled with designated treatments (15 μL volume) or left untreated, as dictated by group assignment. The liquid peptide suspension could easily be seen filling the defect, and defects were filled until visually full. At this time, Lactated Ringer's Solution was added to the joint periphery to gently fill the joint and cause polymerization of the peptide, which was visually inspected to ensure retention of the implant. Dorsal-caudal and lateral-medial 90° radiographs of each stifle joint were obtained immediately after surgery. At 12 weeks, rabbits were euthanized with pentobarbital after sedation. Post-surgical radiographic views were repeated following euthanasia.
Gross Pathologic Observations of Joints
The limbs and joints were examined and graded by a blinded observer (DDF) unaware of treatment group (Table 2) . For the muscle wastage measurement, the limbs were shaved and a flexible tape measure was used in a similar anatomic location of the stifle to make this assessment. This scoring system was chosen in order to compare to other studies performed by Frisbie et al. 6 
Synovial Membrane Histology
Synovial membrane was harvested and placed in neutral-buffered 10% formalin, embedded in paraffin, 5-μm sections created and stained with hematoxylin and eosin (H&E). Sections were evaluated blindly (DDF) for cellular infiltration, vascularity, intimal hyperplasia, subintimal edema and subintimal fibrosis on a scale of 0-4 (0=none, 1=slight, 2=mild, 3=moderate, 4=severe) 42 .
Articular Cartilage Histology and Immunohistochemistry
At the time of necropsy, the circular defect area was cut in half with an Exakt bandsaw. The medial half of the repair tissue with surrounding native tissue was fixed in neutral-buffered 10% formalin for histology, and the lateral half was embedded in OCT and flash frozen for immunohistochemistry.
For histology, the fixed tissue was decalcified, embedded in paraffin, sectioned at 5 μm, and stained with either H&E or Safranin-O, fast green (SOFG) (ThermoScientific/Shandon VeriStain Gemini ES stainer) for proteoglycan visualization. Sections stained with H&E were evaluated blindly (DDF) using a modified O'Driscoll scoring system 6, 43 (Table 3) with a maximum cumulative histology score of 28 and a higher score indicating a repair more like native cartilage. Sections stained with SOFG were evaluated blindly (DDF) for intensity of staining on a scale of 0-3 (Table 3 ) and were included in the cumulative histology score.
For immunohistochemical analyses, frozen tissue was sectioned at 8 μm. Each section was incubated in 0.25 U/mL chondroitinase ABC (Sigma-Aldrich) for 15 min before incubation in primary antibody solution (Collagen I (1:10) #M-38-s and II (undiluted) # II-II6B3-s, Hybridoma Bank; Aggrecan (1:100, Alexis Biochemicals) #ALX-803-313; or rabbit IgG as control). Endogenous peroxidase was blocked using 0.3% H 2 O 2 in methanol. Sections were incubated in goat anti-mouse HRP secondary antibody solution (1:500, Jackson Immunoresearch, Westgrove, PA)), stained with Vector Nova RED (Vector Laboratories, Burlingame, CA) and counterstained with Fast Green. Controls gave no signal. Noncalcified tissues were evaluated blindly (DDF) for the percentage of repair tissue stained positive (0=no stain, 1=1-25%, 2=26-50%, 3=51-75%, 4=76-100%).
Radiographic Analysis
Radiographs and photographs were taken of bone segments from femoral sections. Radiographs were graded for presence of lysis, bony proliferation, osteophyte presence, and patellar luxation, and a total radiographic score was calculated by summing these scores (maximum score of 16). All grading was done on a 0-4 scale (0=none, 1=slight, 2=mild, 3=moderate, 4=severe) 22, 42 . Additionally, radiographs post-euthanasia were scored for healing of the defect (0=no healing, 1=slight healing, 2=mild bone filling, 3=lesion is visible but difficult to measure, 4=lesion not visible to measure), sclerosis around the defect, and other sclerosis (0-4, none-severe). Sclerosis is defined as the increase in density of bone seen radiographically and was subjectively scored by MFB in a blinded fashion.
Statistical Analyses
Scores were evaluated for inter-and intra-group differences using an ANOVA framework with PROC GLIMMIX (fits generalized linear mixed models) of SAS (Cary, NC) 44 with rabbit as a random variable. For all joint pathologic, histological, immunohistochemical, and radiographic analyses, intra-group differences were analyzed with treatment set as the main effect (one-way); differences among groups were analyzed using treatment and group as main effects (two-way). Untreated controls were therefore analyzed separately depending on what treatment the contralateral joint received in order to account for possible systemic effects 45 . When main or interaction effects had p-values that were considered significant (pvalue < 0.05) or a trend (0.05 < p-value <0.10), individual comparisons were made using the least square means procedure 22 . P-values presented in the text include which main effect or interaction term they are referring to if quoted for comparisons among groups. All data are presented as mean ± standard error of the mean (SEM). Non-parametric analyses were also performed when appropriate. The authors were able to reach similar conclusions based on either analysis. Because the authors feel many of the biologic outcome parameters represent more of a continuum rather than defined categories, the parametric analysis of the data is presented.
RESULTS
Radiographic Analyses
Radiographic analyses pre-treatment did not show any sclerosis in any of the rabbits. Treated defects post-treatment showed some slight osteophyte formation (0.3 (0.0, 0.6), treated; 0.1 (−0.2, 0.4), untreated; treatment p=0.087). There was no difference among groups (group p=0.490).
Gross Observation of Joints
Upon necropsy, joints and incision areas in all experimental groups appeared normal by gross examination (Fig 1) , and no inflammation or infection was noted, indicating no adverse immune reaction to the treatments. Repair cartilage appeared to be moderately to normally attached to surrounding cartilage in all defects with no differences between treatments (treatment p=0.299) or groups (group p=0.541) ( Table 4 :XIII). Similarly, repair tissue ranged from normal to slightly-soft compared to surrounding tissue when assessed for attachment to the subchondral bone, with no differences between treatments (treatment p=0.192) or groups (group p=0.970) ( , untreated, treatment p= 0.032) and the level of treated defects was higher than contralateral untreated defects (2.6 (2.3, 3.0), treated; 2.2 (1.8, 2.6), untreated; treatment p=0.050). Untreated defects also had more muscle wastage at the site of incision (assessed by circumferential measurement at the proximal aspect of the patella) (12.9 cm (12.5, 13.2), treated vs. 12.7 cm (12.3, 13.0), untreated; treatment p=0.001), with group 1 and 3 treated defects different from their respective contralateral controls (Table  4 :III; interaction p=0.032). Treated defects were scored higher in grade of repair compared to contralateral untreated defects, equivalent to a score of good (3.0 (2.6, 3.5), treated vs. 2.5 (2.0, 2.9), untreated, on a scale of 0-4; treatment p=0.061).
Histologic Examinations
Synovial Membrane H&E: Evaluation of the synovial membrane by H&E staining showed some mild intimal hyperplasia and some mild to moderate vascularity and subintimal fibrosis, but there were no differences among any groups or treatments. Articular Cartilage H&E: Assessment of the articular cartilage H&E staining showed that KLD (group 1) had a higher cumulative histology score compared to contralateral untreated controls when looking at that group alone ( Table 5 :XII, p=0.034). Overall, when comparing among groups, KLD and KLD+CF (groups 1 and 2) had higher cumulative scores than KLD +CF+BMSCs (group 3) ( Table 5 :XII, group p=0.030). Defects treated with KLD received the highest score for nature of predominant tissue in the defect (see Tables 3, 5 :I), which was similar to fibrocartilage. The other groups and treatments ranged between 0 and 1, indicating presence of some fibrocartilage and some non-chondrocytic cells; however, none of the groups or treatments were significantly different ( (Tables 3,5 :VIII, group p=0.015). Group 2 had more reconstitution of subchondral bone than group 3 (group p=0.030), but all groups were still below normal subchondral bone levels (Tables 3,5: IX); treated defects trended higher than untreated defects (1.9 (1.5, 2.2) treated; 1.5 (1.1, 1.8) untreated; treatment p=0.074). Group 2 also showed the highest score for bonding to adjacent cartilage ( Articular Cartilage SOFG-Defects treated with KLD-alone (group 1) had increased Safranin-O staining (scores of slight to moderate staining) than the contralateral untreated defects or treated defects in groups 2 and 3, which had only none to slight staining (Table  5 :XI, interaction p=0.011). There was no overall effect of treatment or group on this measure (treatment p=0.286, group p=0.604). As shown in Fig 2, treatment with KLD-alone resulted in greater staining throughout the repair tissue.
Immunohistochemistry Evaluations
Looking at only group 1, defects treated with KLD showed increased collagen II immunostaining compared to contralateral untreated defects ( Table 6 :III, p=0.028); although aggrecan immunostaining for defects treated with KLD received a score of 2.7, it was not different from the contralateral untreated control ( Table 6 :I, p=0.526). This is in contrast to the difference observed in Safranin-O staining between defects treated with KLD and the contralateral untreated defects. In group 2, KLD+CF treatment elicited a tissue with higher aggrecan detected by immunostaining vs. the contralateral untreated control ( Table 6 :I, p=0.041). In addition, although defects treated with KLD+CF received the highest collagen II immunostaining score of all the groups, 3.4, this was not different from its contralateral untreated control (Table 6 :III, p=0.110). Comparing all defects, treated defects had more collagen II (2.9 (2.2, 3.6) treated; 1.6 (0.9, 2.2) untreated; treatment p=0.001) and increased aggrecan (2.9 (2.3, 3.4) treated; 2.1 (1.6, 2.7) untreated; treatment p=0.056) compared to untreated defects; there were no differences among groups (group p=0.293). There were similar levels of collagen I immunostaining found in all the defects (treatment p=0.471, group p=0.919), consistent with the observation of mostly fibrocartilage seen in the gross scoring ( Table 6 :II). Overall, within the repair tissues, collagen II immunostaining was observed deeper in the sections and collagen I immunostaining was seen more in the superficial. Aggrecan immunostaining was noted to have a more generalized distribution, but more positive staining was seen deeper in the repair tissue.
DISCUSSION
Treatment of full-thickness articular cartilage defects with the self-assembling peptide KLD (group 1) markedly improved cartilage regeneration, as seen by significant increases in cumulative histology score, Safranin-O staining, and collagen II immunostaining, compared to critically-sized contralateral untreated defects. KLD has several advantages as a material due to its ability to be injected arthroscopically into a defect, assemble on contact with tissue, and promote cartilage regeneration without inducing an immune response. Adding TGF-β1, dexamethasone, and IGF-1 to KLD (group 2) resulted in increased aggrecan immunostaining compared to its contralateral untreated defect, but in general did not result in any additional beneficial or deleterious effects compared to KLD alone (group 1). Motivated by in vitro results supporting BMSC chondrogenesis 33, 34, 38 , we delivered these factors with allogeneic BMSCs in KLD in vivo (group 3). However, this treatment resulted in a poorer repair than with KLD or KLD+CF. This is similar to other reports of fibrous tissue formation after BMSC treatment 23, 24, 26 , interpreted as a negative result. In our rabbit model, the presence of a full-thickness defect allowed bone marrow to infiltrate the defect 46 and act as a cell source, similar to abrasion arthroplasty and subchondral bone microfracture surgical techniques. The positive healing response seen with KLD treatment (group 1) demonstrates that the scaffold supports cell migration and further chondrogenesis of these cells in vivo. The high porosity of this scaffold (~99.6% water content 31 ) is in agreement with a recent in vivo study in rabbits by Ikeda et al. 47 demonstrating that scaffolds with >85% porosity promoted migration of bone marrow cells into polymer scaffolds and with an in vitro study by Wang et al. 48 demonstrating endothelial cell migration into several types of self-assembling hydrogels.
Regarding group 2, KLD+CF treatment, our results raise the issues of whether the CF dose was appropriate to improve endogenous cell response and whether cells migrating into the scaffold in vivo respond differently to these CFs than in vitro and thereby require different stimulation. The inclusion of CFs did not show increased chondrogenesis over KLD alone (group 1) as determined by cumulative histology score, Safranin-O, aggrecan, and type II collagen immunostaining. Similar to these results, Holland et al. 13 reported that TGF-β1 and IGF-1 delivered in gelatin microparticles within an acellular oligo(poly(ethylene glycol) fumarate) (OPF) scaffold resulted in repair no different than in empty defects, despite positive results in vitro. That study also delivered IGF-1 alone and found that this growth factor alone resulted in a significantly improved repair. In addition, other studies have looked at delivering IGF-1 alone in vivo and have reported similar positive results 4, 16 . While we did not test the effects of IGF-1 alone in this study, our results emphasize the need for further understanding of the combination of IGF-1 with other CF in vivo in order to take advantage of its characteristic anabolic properties.
The intra-articular use of TGF-β1 remains controversial due to the pro-inflammatory response by the synovium seen at certain concentrations. Van der Kraan and van den Berg et al. have studied the interaction of TGF-β1 with various joint tissues and have shown that while TGF-β1 can stimulate proteoglycan production in cartilage, when it is exposed to synovial tissue, synovial fibrosis can occur; TGF-β1-induced osteophyte formation is also common 18 . Mi et al. 17 showed that injection of recombinant adenoviral vector for hTGF-β1 into the knee joint space through the patellar tendon (resulting in ~8.75 ng TGF-β1) dramatically increased joint inflammation, though this dose is more than 6-fold higher than our total dose of 1.4 ng. Accordingly, we did not observe these effects when TGF-β1 was added to the peptide alone (group 2). In contrast, when TGF-β1 was added in combination with BMSCs (group 3), osteophyte formation increased, suggesting an interaction of TGF-β1 with these cells was responsible for the increased osteogenesis rather than the presence of TGF-β1 alone in the joint (group 2). This finding is similar to results recently published by Guo et al. 27 , in which 600 ng of TGF-β1 per mL of hydrogel was used in combination with BMSCs in an OPF scaffold. Furthermore, we observed a detrimental increase in osteophyte formation and distortion of normal joint anatomy when, in the same rabbit, 1.4 ng TGF-β1+BMSCs were placed in one joint and 0.7 ng TGF-β1+BMSCs in the contralateral joint 49 . The authors were surprised at this result given the total body dose of TGF-β1 was only 1.5x what was used in group 2 or group 3 and the cell numbers 2-fold greater. While the amount of TGF-β1 delivered in group 3 of our study was lower than that in the Mi 17 study, and we attempted to deliver TGF-β1 in a controlled fashion, it is still possible that this TGF-β1 level was too high to beneficially induce chondrogenesis when combined with BMSCs, despite the inclusion of dexamethasone, which has been shown to enhance chondrogenesis compared to TGF-β1 alone 9, 50 . A study by Fan et al. using only 0.8 ng of TGF-β1 with BMSCs in a gelatin-chondroitin-hyaluronate tri-copolymer scaffold reported improved rabbit cartilage defect healing compared to treatment with BMSCs implanted in a scaffold without TGF-β1. Taken together, these studies suggest that while the amount of TGF-β1 we chose combined with BMSCs effectively induces chondrogenesis in vitro 38 , additional research is needed to determine a successful strategy for optimizing chondrogenesis of BMSCs in vivo, and interactions with synovial tissues must be considered.
Due to the often noted ability of cartilage defects in young/skeletally immature rabbits to heal well naturally 46 , we used skeletally mature rabbits with average age of 11 months and critically-sized defects in order to test the ability of treatment to improve adult animal healing. Although full-thickness defects were used, defects only entered the subchondral/ trabecular bone, resulting in contralateral untreated defects that do not heal spontaneously by 12 weeks. These results are similar to other studies using similar-aged rabbits and defect sizes. A limitation of our model is the lack of enough tissue to perform direct biochemical assessment in addition to histological and immunohistochemical measurements in this study. However, the purpose of the present study was to perform an initial trial prior to a larger animal study where such additional measures will be utilized, since ample tissue will be available.
In summary, the self-assembling peptide hydrogel KLD offers a new material suitable for further testing in a clinically relevant defect in a large animal. We demonstrated improved filling of osteochondral defects and improved cartilage repair, as seen by cumulative histology score, Safranin-O staining, and type II collagen immunostaining. In this small animal model, the full-thickness defect provided access to the marrow, similar in concept to abrasion arthroplasty or spongialization in large animal models (goat, sheep, horse, human), and suggests that combining KLD with these techniques may offer an improvement over current practice. Ongoing studies include the evaluation of KLD in a clinically relevant sized equine defect co-treated with microfracture and subjected to strenuous exercise, compared to defects treated with microfracture alone. Gross necropsy photographs of treated and untreated joints in KLD, KLD+CF, and KLD +CF+BMSCs. Safranin-O staining. Images showing histological evaluation of representative treatment groups and representative contralateral control knees. Treatment and contralateral pictures were representative of the mean scores and were taken from different animals for KLD and KLD+CF+BMSCs, and from the same animal for KLD+CF. Scale bar = 1 mm. Table 1 Treatment groups with amounts delivered per animal. Gross Observations Scoring System.
Feature Score
I. Joint Observation
Normal appearance 0
Slight inflammation 1
Moderate inflammation 2
Severe inflammation 3
II. Incision Appearance
Moderate inflammation 2
Slight dehiscence (incision basically intact) 4
Marked dehiscence (requires intervention) 5
Active infection 6
Healing infections 7
III. Muscle wastage at the time of necropsy in treated vs untreated limbs
Circumferential measurement at the proximal aspect of the patella (cm)
IV. Angle of Stifle: Change in normal angle (if any)
None, within normal limits 0 Abnormal 1
V. Inflammation/Swelling
VI. Trauma/Damage
VII. Infection/Discharge
VIII. Presence of Osteophytes and other Osteoarthritic Changes
IX. Articular Surface Integrity, Contour, and Congruity
Normal 0
Abnormal 1
X. Presence of Loose Bodies in Synovial Fluid
XI. Injury to Apposing Articular Surface
None, within normal limits 0
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Feature Score
Abnormal 1 
XII. Synovial Membrane Appearance
XVIII. Grade (Overall quality of repair)
This category describes the overall subjective evaluation of the repair tissue by the evaluator.
Criteria used to determine the grade were:
(1) Attachment of repair tissue to the surrounding normal articular cartilage Osteoarthritis Cartilage. Author manuscript; available in PMC 2012 January 12. Gross Scores. Histological Scores. TXT: 0.001 Group: 0.293 TXT*Group: 0.551
One-way p-values for within group comparisons are listed in the untreated columns. Two-way p-values for differences among groups are in a separate column (TXT = treatment, Group = group, TXT*Group = interaction term). Mean and confidence intervals calculated during two-way analysis are shown.
